Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTI-2040 + Capecitabine in Metastatic Breast Cancer
NCT00068588Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2003
- Primary completion
- Mar 2010
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of GTI-2040 in breast cancer, sponsored by National Cancer Institute. Started Oct 2003; status: completed.
02
Drugs
GTI-2040
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00068588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068588.